Fc-Silenced Anti-Mouse PD-1 (CD279) Antibody (Mouse IgG2a κ LALAPG, RMP1-14.1) | PA007162.m2aLA

Catalog No.	PA007162.m2aLA
Product Name	In Vivo Grade Recombinant Anti-mouse PD-1 Monoclonal Antibody (Clone RMP1-14.1), Mouse IgG2a-L234A L235A P329G (LALAPG) Kappa
Data Sheet	📄 Download Product Data Sheet (PDF)
Supplier Name	Syd Labs, Inc.
Brand Name	Syd Labs
Synonyms	Fc-Silenced Anti-Mouse PD-1 Monoclonal Antibody, Fc-Null Anti-Mouse PD-1 Antibody, Fc-Inert Anti-Mouse PD-1 Antibody, Effectorless Anti-Mouse PD-1 Antibody, Anti-Mouse CD279 Antibody, Anti-Mouse PD-1 LALAPG Antibody, Anti-Mouse PD-1 LALA-PG Antibody, Mouse IgG2a LALAPG Anti-PD-1, Anti-Mouse PD-1 L234A/L235A/P329G Antibody, Recombinant Chimeric Anti-Mouse PD-1 Antibody, In Vivo Anti-PD-1 RMP1-14.1
Summary	The In Vivo Grade Recombinant Anti-mouse PD-1 Mouse IgG2a-L234A L235A P329G (LALAPG) Kappa Monoclonal Antibody (Clone RMP1-14.1) was produced in mammalian cells.
Clone	RMP1-14.1, the same variable region sequences as the rat anti-mouse PD-1 monoclonal antibody (clone number: RMP1-14)
Isotype	mouse IgG2a, kappa
Applications	immunohistochemistry (IHC), Flow Cytometry (FC), and various in vitro and in vivo functional assays.
Immunogen	The original rat hybridoma (clone name: RMP1-14) was generated by immunizing rats with mouse PD-1-transfected BHK cells.
Form Of Antibody	0.2 μM filtered solution of 1x PBS.
Endotoxin	Less than 1 EU/mg of protein as determined by LAL method.
Purity	>95% by SDS-PAGE under reducing conditions.
Shipping	The In Vivo Grade Recombinant Anti-mouse PD-1 Mouse IgG2a-L234A L235A P329G (LALAPG) Kappa Monoclonal Antibody (Clone RMP1-14.1) are shipped with ice pack. Upon receipt, store it immediately at the temperature recommended below.
Stability & Storage	Use a manual defrost freezer and avoid repeated freeze-thaw cycles. 1 month from date of receipt, 2 to 8°C as supplied. 3 months from date of receipt, -20°C to -70°C as supplied.
Note	Recombinant anti-mouse PD-1 / CD279 monoclonal antibodies, which combine the identical variable region sequence of the rat clone RMP1-14 with a mouse IgG2a kappa constant region carrying Fc-silencing L234A/L235A/P329G (LALAPG) mutations (chimeric Fc-silenced format), are expressed in mammalian cells. Recombinant rat, chimeric mouse (intact-Fc and Fc-silenced LALAPG mutant) and low-effector mouse IgG1 versions are also available.
Order Offline	Phone: 1-617-401-8149 Fax: 1-617-606-5022 Email: message@sydlabs.com Or leave a message with a formal purchase order (PO) Or credit card.

Description

References of Fc-Silenced Anti-Mouse PD-1 (CD279) Antibody (Mouse IgG2a LALAPG, Clone RMP1-14.1)

The references below are peer-reviewed publications covering three core aspects of this Fc-silenced anti-mouse PD-1 (CD279) reagent: studies demonstrating FcγR-mediated effector functions (ADCC/ADCP/CDC) and activated CD8⁺ T cell depletion that motivate Fc-null / Fc-inert formats; publications using the parent RMP1-14 clone for in vivo PD-1 blockade across syngeneic tumor models; and comparator studies using Fc-competent anti-mouse PD-1 antibodies for effector-dependent applications. This product carries L234A/L235A/P329G (LALAPG) mutations to abolish FcγR and C1q binding, and shares the identical RMP1-14.1 variable region sequence with antibodies used in these studies, with experimental protocols, dosing regimens and mechanistic conclusions directly translatable to experiments requiring pure PD-1 blockade without Fc effector confounding.

1. Macrophages Impair TLR9 Agonist Antitumor Activity through Interacting with the Anti-PD-1 Antibody Fc Domain
Simone Camelliti, et al. Cancers (Basel) 2021. doi: 10.3390/cancers13164081
“We evaluated the contribution of macrophages to the effect of combinatorial immunotherapeutic treatments based on TLR9 stimulation (with CpG-ODNs) and PD-1 blockade in an ovarian cancer preclinical model. We observed a strong reduction in the antitumor efficacy of a TLR9 agonist upon anti-PD-1 antibody administration. Specifically, we found that TLR9-stimulated macrophages, through interacting with the fragment crystallizable (Fc) domain of the anti-PD-1 antibody, acquire an immunoregulatory phenotype leading to dampening of CpG-ODN antitumor effect.”

2. Antibody-mediated depletion of programmed death 1-positive (PD-1+) cells
Yan Zhai, et al. J Control Release 2022. doi: 10.1016/j.jconrel.2022.07.010
“Anti-PD-1 antibodies are typically used to block inhibitory signals in dysfunctional T cells. Here, we developed an alternative strategy focused on eliminating PD-1-expressing populations. Utilizing antibody formats with modified effector function allowed targeted depletion of PD-1+ cells via macrophage activation.”

3. Decoupling FcRn and tumor contributions to elevated immune checkpoint inhibitor clearance in cancer cachexia
Thanh T. Vu, et al. Pharmacol Res 2024. doi: 10.1016/j.phrs.2023.107048
“Cancer cachexia accelerates the clearance of multiple monoclonal therapeutic antibodies, reducing exposure. We assessed the specific contributions of target burden and FcRn-mediated recycling dynamics. Our findings outline that cachexia altered antibody elimination tracks independently of typical target receptor distributions.”

4. Diphtheria toxin‐derived, anti‐PD‐1 immunotoxin, a potent and practical tool to selectively deplete PD‐1+ cells
Tao Zhang, et al. Protein Sci 2023. doi: 10.1002/pro.4741
“Investigating the roles of chronic PD-1+ populations requires reliable depletion methods. We engineered a diphtheria toxin-based immunotoxin architecture targeting mouse PD-1 structures. This molecule mediates rapid, highly specific systemic elimination of active PD-1-positive subgroups inside immunocompetent strains.”

Other Formats

All variants below share identical RMP1-14.1 variable region sequences and mouse PD-1 (CD279) binding specificity. They differ only in Fc isotype and Fc effector function — choose the format that matches your experimental readout and mouse strain.

How to choose a format: Use an intact-Fc format (r2a, m2a, m2c) when your readout requires full Fc-mediated effector activity (ADCC/ADCP/CDC), and note that mouse IgG2c matches the C57BL/6 (Igh-1b) allotype commonly used in MC38 and B16-F10 models, while mouse IgG2a matches BALB/c (Igh-1a) backgrounds such as CT26. The low-effector wild-type mouse IgG1 format (m1) is suited to functional PD-1 blockade with minimal FcγR engagement, without full Fc silencing. Use an Fc-silenced format (m1DA, m2aLA, m2cLA) — carrying L234A/L235A/P329G (LALAPG) or D265A mutations to abolish FcγR and C1q binding — when you need pure PD-1 blockade without Fc-receptor engagement, ADCC/ADCP/CDC confounding, or FcγR-mediated depletion of activated CD8⁺ T cells.

Ushelf Advisor

AI-generated answers, based on peer-reviewed literature and Ushelf product data. These FAQs cover isotype selection, LALAPG Fc-silencing mechanism, in vivo experimental parameters, handling, and control selection for PA007162.m2aLA — our Fc-silenced anti-mouse PD-1 (CD279) monoclonal antibody (mouse IgG2a κ L234A/L235A/P329G, clone RMP1-14.1). This section is provided as a research reference. Please verify critical parameters — dosing, working dilutions, buffer conditions — against the primary references, or confirm with our technical support before finalizing an experimental design. Last updated: October 23, 2026.

Q: What is the difference between PA007162.m2aLA and rat IgG2a anti-mouse PD-1 antibodies such as PA007162.r2a?

Both carry the identical RMP1-14 variable region. PA007162.m2aLA pairs it with a mouse IgG2a kappa constant region bearing the LALAPG (L234A/L235A/P329G) Fc-silencing mutations, whereas PA007162.r2a retains an intact rat IgG2a Fc with ADCC/CDC-competent effector function. Replacing the rat constant region with the species-matched mouse IgG2a backbone reduces anti-rat constant-region responses on repeated dosing, and Fc silencing removes FcγR/C1q binding for strictly non-depleting PD-1 blockade.

Q: What is the significance of the LALAPG (L234A L235A P329G) mutations in PA007162.m2aLA?

The LALAPG triple mutation in the mouse IgG2a Fc domain disrupts the Fc/FcγR interface and abolishes both FcγR and C1q binding, preventing Fc-mediated effector functions — ADCC, ADCP and CDC — and FcγR-mediated depletion of activated CD8⁺ T cells, to ensure strictly non-depleting, blocking-only PD-1 inhibition. P329G is essential for C1q inactivation, which is why the triple (LALAPG) rather than the LALA pair alone is used.

Q: Is my anti-mouse PD-1 antibody Fc-silenced, and what does it mean for my study?

PA007162.m2aLA is an Fc-silenced (Fc-null / Fc-inert) anti-mouse CD279 (PD-1) antibody. It is intended for experiments in which FcγR engagement would confound readouts — for example when Fc-mediated depletion of activated CD8⁺ T cells could mask the effect of pure checkpoint blockade. If instead you require intact effector function, choose the Fc-competent formats r2a, m2a, m2c or m1.

Q: Is PA007162.m2aLA suitable for in vivo preclinical research?

Yes. This Fc-silenced anti-mouse CD279 (PD-1) monoclonal antibody is expressed in mammalian cells as an in vivo grade reagent with high purity (>95% by SDS-PAGE) and ultra-low endotoxin levels (<1 EU/mg by LAL method), and is validated for in vivo functional assays, flow cytometry (FC) and immunohistochemistry (IHC).

Q: What specific clone characteristics and origin does PA007162.m2aLA have?

It is designated as clone RMP1-14.1, retaining the exact same variable region sequences as the classic rat anti-mouse PD-1 clone RMP1-14, which was originally generated by immunizing rats with mouse PD-1-transfected BHK cells.

Q: Which isotype control should be used with PA007162.m2aLA?

A matching mouse IgG2a-L234A L235A P329G (LALAPG) isotype control is recommended, so that the control carries the same Fc-silenced backbone and the same concentration and buffer. A mouse IgG2a LALAPG isotype control is available for direct pairing with PA007162.m2aLA.

Q: What is the recommended in vivo dosage for PA007162.m2aLA?

In mouse syngeneic tumor models, anti-mouse PD-1 antibodies are commonly dosed at 200 µg per mouse intraperitoneally every 3 days, with a frequently cited range of 200–500 µg per mouse. Optimal dosing and schedule should be determined for each model and study design.

Q: How is PA007162.m2aLA formulated, shipped, and stored?

It is supplied as a 0.2 µm filtered solution in 1× PBS, shipped with ice packs. Store in a manual defrost freezer at 2–8°C for short-term use (up to 1 month) or at -20°C to -70°C for extended storage (up to 3 months), avoiding repeated freeze-thaw cycles.